

Tuesday 18th Jun 2024



Today's issue of *PD*

Pharmacy Daily today features three pages of news, plus full pages from:

- Pointrs
- Perrigo

Earn more points

PHARMACISTS can save money on airline and hotel stays with Pointrs, which is offering 125% more loyalty points when paying wholesalers with an American Express card.

See more on page four.

Delayed ovulation

PERRIGO'S emergency contraception medicine EllaOne is most effective in the 24 hours after intercourse and can delay ovulation.

It is also the preferred choice for those with a BMI≥26kg/m2. See more on the **back page**.

APC prioritises public safety at PCS24

EXCLUSIVE

MAINTAINING high standards and the accreditation of pharmacists play a key role in reinforcing public safety and building the skills and knowledge of graduates entering the industry, Australian Pharmacy Council (APC) CEO Bronwyn Clark (pictured left) told *Pharmacy Daily*.

Clark said with the healthcare sector undergoing changes, including expanding scope of practice and workforce shortages, the council's role is to maintain high proficiency.

"Our job is to ensure safety remains a priority, that programs and training are delivered to a high standard, and that upon registration, every pharmacist has been assessed according to Australian standards," Clark added.

To ensure future pharmacists are well prepared, the APC develops and administers evidence-based exams essential for registration.



Recognising the importance of supporting overseas-trained pharmacists, the APC has also established a candidate engagement team to assist these individuals through the early stages of their registration process.

It is this level of deep involvement that Joe Cashman (pictured), Director of Candidate Engagement, noted that the APC will bring when it participates in the upcoming Pharmacy Careers Summit (PCS24) on 05 Jul.

"We are delighted to be part



of the summit this year and look forward to engaging with our candidates," Cashman said.

Presented by Raven's Recruitment and *Pharmacy Daily*, PCS24 will also help attendees network with industry leaders and peers, opening doors to new career opportunities and collaborations, which will assist pharmacists to tackle future healthcare challenges.

The free, virtual PCS24 is a must-attend event for aspiring professionals with registrations open - to see more, **CLICK HERE**. *JG*





Tuesday 18th Jun 2024

AMA Aged Care For any and a second care and a s

AMH Aged Care Companion

Evidence-based information to address the most common agerelated illnesses and drug treatment challenges.

amh.net.au

AUSTRALIAN NEGICI NESTRANDE

NSW trial expands to skin

PHARMACISTS across New South Wales will soon be able to treat four specific skin conditions as part of the expanded NSW Pharmacy Trial.

Luke Kelly, President of the Pharmaceutical Society of Australia (PSA) New South Wales, expressed strong support for this expansion.

"Community pharmacists will be trained to treat four skin conditions, making treatment for conditions like impetigo, shingles, eczema, and mild plaque psoriasis more accessible across our state," Kelly said.

He emphasised the critical role pharmacists play in strengthening the healthcare system, highlighting the benefits of the NSW Pharmacy Trial in providing safe treatment.

"For skin conditions like shingles, acute eczema, mild plaque psoriasis, and impetigo, timely treatment is essential to relieve discomfort, prevent complications, and improve patient outcomes," commented Kelly.



He noted that New South Wales pharmacists have already supported thousands of patients with various health concerns, including uncomplicated urinary tract infections (*PD* 14 May) and resupply of oral contraceptives.

The inclusion of skin conditions in the trial will further enhance pharmacists' ability to offer accessible care.

The expansion also includes increased remuneration for pharmacists providing consultations for skin conditions, reflecting their clinical expertise and the costs of administration.

"Increased support for pharmacists ensures these services remain available to patients across the state at no cost," Kelly said.

To learn more, CLICK HERE. JG

Early bird rates closing for Guild events

WITH just two weeks remaining, the early bird discounts for the Pharmacy Connect and Pharmacy Assistant National Conference (PA2024) are set to expire on 30 Jun.

Convenor Kos Sclavos (**pictured**) urges potential attendees to take swift action to secure their spots at these industry events.

Pharmacy Connect and PA2024, hosted annually by the Pharmacy Guild of Australia, will be held from 05 to 07 Sep at the Hyatt Regency Sydney.

Pharmacy Connect is a pivotal event for pharmacists, pharmacy owners, executives, students, interns, and industry representatives, while PA2024 serves as the premier gathering for pharmacy assistants.

Sclavos highlighted the urgency, noting, "June is flying by, but there's still a little time left for people to save on registrations".

Pharmacy Connect, themed "Connect today,



shape tomorrow," features a comprehensive education program, pre-conference workshops, a 70-stand trade exhibition, and social events like the welcome reception and cocktail party.

Key speakers include Australian Olympian Peter Bol and financial journalist Effie Zahos.

PA2024 offers a three-hour refresher training workshop on sales techniques and product updates, motivational and management-focused sessions, and the announcement of The Pharmacy Guild of Australia/ Maxigesic Pharmacy Assistant of the Year Award National Winner.



We are excited to share the latest episode of our podcast, where we delve into the fascinating journey of Cathie Reid AM - from her beginnings as a pharmacist to becoming a groundbreaking entrepreneur and a future astronaut with Virgin Galactic.



YOUR PHARMACY CAREER PODCAST





Tuesday 18th Jun 2024

LIKE US ON FACEBOOK Pharmacy Daily





Dispensary Corner

A 63-year-old man had a major breakfast mishap when he sneezed and coughed, and found his colon made a surprise exit.

The man, enjoying a meal with his wife at a diner in Florida, felt a 'wet' sensation and sharp pain.

Fresh off an abdominal surgery and assured that his incision had healed, he lifted his shirt to reveal several inches of his colon making a shocking appearance through the surgical wound.

Paramedics arrived to find a three-inch opening with a large amount of bowel showing.

Thankfully, blood loss was minimal, the colon was undamaged, and he was whisked off to the hospital where surgeons promptly tucked his bowel back in.

Dehiscence, or the reopening of a surgical wound, is rare but can happen and be serious.

The American Journal of Medical Case Reports, which published the case, noted that coughing often triggers such dangerous events.

The gentleman, who had earlier battled prostate cancer and undergone multiple surgeries, had just had his stitches removed that morning.

He and his wife had gone to the diner to celebrate his clean bill of health with breakfast.

To prevent another escape attempt by his organs, surgeons used the strongest closures figure-of-eight stitches, with internal and external stitching that penetrates multiple layers of the abdominal wall.

It seems this time, breakfast will stay where it belongs.

Telix backs out of listing

TELIX Pharmaceuticals, one of Australia's largest biotechnology companies, has announced it has withdrawn its plans to raise USD \$200 million (A\$300 million) and list on the Nasdag.

The company cited that the proposed discounted prices did not align with its duty to shareholders.

Six months ago, the Melbournebased biotech, which has a market capitalisation of \$5.4 billion, revealed its consideration of an initial public offering (IPO) on the Australian Stock Exchange.

Last week, Telix stated it decided not to proceed with the transaction under the current market conditions, emphasising that the intention to list on Nasdag was not driven by a need to raise capital.

Since announcing its intent to file in early Jan, Telix has

achieved several milestones, including promising therapeutic trial results and the \$188 million acquisition of US-based therapeutic radiopharmaceuticals firm QSAM

Additionally, three months ago, Telix acquired Canada-based radioisotope production tech firm ARTMS for \$86 million.

"While this is not our desired outcome, Telix's strategic objectives must align with our duty to existing shareholders," said Managing Director and CEO Dr Christian Behrenbruch.

Founded in 2015 and with operations around the world, Telix manufactures Illuccix, a product used in the detection and diagnosis of prostate cancer, approved by the US FDA, the Australian TGA, and Health Canada. JG



Time to renew your Guild membership

IT'S that time of the year again with memberships up for renewal to the Pharmacy Guild of Australia.

Membership means continued access to an exclusive suite of practical tools and expert advice designed to streamline your daily operations and drive your pharmacy's growth.

Our dedicated team of workplace relations advisors offer expert guidance across critical areas such as employment processes, wages, employer obligations, and more.

Plus, your membership includes complimentary access to the Australasian College of Pharmacy, ensuring you stay at the forefront of clinical practice, and a free Employee Assistance Program available to all members and their staff.

With your Guild membership, you receive timely updates on key issues and insights, empowering you to focus on what truly matters - growing your business.

You're not just maintaining membership; you're continuing with a trusted partner dedicated to your success, your community's health, and the advancement of community pharmacy nationwide.

No matter the challenge, the Guild is here to support every aspect of your pharmacy.

Renew your membership before 30 Jun to avoid disruption of service.





www.pharmacydaily.com.au

Pharmacy Daily is part of the **Business Publishing Group family** of publications

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL

Editor - Jayamala Gupte Deputy Editor - Matt Lennon Journalists - Adam Bishop, Myles Stedman, Janie Medbury, Matthew Wai Editor-at-large - Bruce Piper Publisher - Damian Francis

Associate Publisher - Jo-Anne Hui-Miller

ADVERTISING AND MARKETING Head of Sales & Marketing - Sean Harrigan Advertising - Laura Aghajanian & Dante Muranty

advertising@pharmacydaily.com.au

Head of Operations & Contributing Editor - Anna Piper

ACCOUNTS

accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia Tel: 1300 799 220 (+61 2 8007 6760)

info@pharmacydaily.com.au



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Damian Francis.

paintrs

Earn up to 3.5x more airline and credit card loyalty points.



Earn 125% More Airline And Hotel Loyalty Program Points/Miles When Paying Pharmacy Wholesalers

Do you own a pharmacy and use a wholesaler-branded American Express card to pay your wholesaler bill?

This Pointr will show you how you can earn 125% more American Express Membership Rewards Points, which you can convert to 125% more airline and hotel loyalty program points and miles, without spending any more at your wholesaler. Fly and stay more than twice as often as before or upgrade to luxury.

Browse
3000+
Pointrs
and see for yourself.


Earn More. Spend Less. Travel Better. www.pointrs.com

ElaOne® IS MORE 2.5X EFFECTIVE THAN LEVONORGESTREL WITHIN THE FIRST 24 HOURS 1/2



Oral emergency contraception works by delaying ovulation

- Luteinising Hormone (LH) surge triggers ovulation however it is difficult to predict when this will occur.^{3,4}
- Only 12% of women ovulate on Day 14.^{3,4}
- EllaOne® can prevent ovulation, even after the LH surge has started.



Delay of follicular rupture for 5 days

EllaOne® is approved for use up to **120 hours**²



5 DAYS LNG is ONLY approved for use up to 72 hours⁵



3 DAYS

ARE YOU STOCKING

AUSTRALIA'S MOST EFFECTIVE ORAL EMERGENCY CONTRACEPTIVE?

- 90% of Women ask for Emergency Contraception in the first 24 hours after unprotected intercourse.⁴
- EllaOne is most effective within 24 hours after unprotected sex.1-2
- UPA, the active ingredient in EllaOne, delays ovulation more effectively than LNG, to reduce the risk of falling pregnant.¹⁻³
- EllaOne is the preferred option for Oral EC in patients with a BMI >26kg/m² or weight >70kg.⁸

CPD MODULES AVAILABLE

via **GuildEd** & **Australasian College of Pharmacy**



ASK YOUR PHARMACIST ABOUT THIS PRODUCT.

References: 1. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis [published correction appears in Lancet. 2014 Oct 25;384(9953):1504]. Lancet. 2010;375(9714):555-562. 2. EllaOne Product Information. Last date of revision 15 November 2021. 3. Cooper GS, Ephross SA, Weinberg CR, Baird DD, Whelan EA, Sandler DP. Menstrual and reproductive risk factors for ischemic heart disease. Epidemiology. 1999;10(3):255-259. 4. Trussell J, Rodríguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception. 1998;57(6):363-369. 5. Norlevo Product Information. Last date of revision 09 January 2020. 6. Nappi RE, Lobo Abascal P, Mansour D, Rabe T, Shojai R; Emergency Contraception Study Group. Use of and attitudes towards emergency contraception: a survey of women in five European countries. Eur J Contracept Reprod Health Care. 2014;19(2):93-101. 7. Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled

data from three randomized trials of emergency contraception regimens. Contraception. 2013;88(5):611-618. **8.** Pharmaceutical Society of Australia. Non-prescription medicine treatment guideline: Emergency contraception. Canberra: PSA; 2022. Perrigo Australia. ABN 56009293136. 25-29 Delawney Street, Western Australia, 6021, AUSTRALIA. MAT-3286.

